This week, the European Medicines Agency (EMA) gave a green signal to AstraZeneca’s upgraded version of Trixeo Aerosphere. The inhaler treats chronic obstructive pulmonary disease (COPD), often known as “smoker’s lung”. It mainly affects cigarette smokers, but it can also hit people exposed to air pollution or dusty workplaces.
So, what’s new?
It’s not the medicine inside that changed—it’s the gas that pushes the medicine into the lungs.
In simple terms, the new inhaler will use a next-gen propellant made by Honeywell. This new gas is better for the planet. It has 99.9% less global warming impact than older propellants used in current inhalers. That means fewer harmful gases in the air while still giving patients the same relief.
AstraZeneca said trials showed the new version works just as well as the old one. Even better, it showed no new safety risks.
The company also said that British regulators approved the eco-version of Trixeo back in May. That made it the first inhaler in the world to use the new low-carbon propellant. Now, Europe could be next.
Also Read Novartis to Develop New Anti-Inflammatory Pills in $1 Billion Matchpoint Deal
The Committee for Medicinal Products for Human Use (CHMP), which advises the EMA, has recommended the EU to approve it. The final decision will come from the European Commission. They usually follow CHMP’s advice, but they still have the final word.
If the Commission gives the go-ahead, this will be the first green inhaler of its kind in the EU.
Ruud Dobber, a senior AstraZeneca executive, said this move helps both “patients and the planet.” It’s part of the company’s bigger push to go green.
Let’s not forget the numbers. Trixeo Aerosphere brought in $978 million in 2024. So, this isn’t a small side project. It’s a big deal for AstraZeneca—and for millions of COPD patients.
The company is now getting ready to roll out the new inhaler across Europe.
This move also puts pressure on other companies like GSK’s Trelegy Ellipta, Sanofi-Regeneron’s Dupixent, and Verona Pharma’s Ohtuvayre. The race for greener medicines has officially begun.
By switching to a low-impact propellant, AstraZeneca is showing the world that healthcare can also be climate-friendly.
It’s a small change inside a tiny device—but it might just be a giant leap for both patients and the planet.
Also Read AstraZeneca to Invest $50 Billion in US Amid Manufacturing Push and Tariff Threat
